<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928199</url>
  </required_header>
  <id_info>
    <org_study_id>201306111</org_study_id>
    <secondary_id>50669</secondary_id>
    <nct_id>NCT01928199</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant</brief_title>
  <official_title>A Single Center, Randomized, Double-blind Controlled Trial of Sitagliptin Versus Placebo to Reduce the Incidence and Severity of New-onset Diabetes After Kidney Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sitagliptin is effective in preventing the&#xD;
      development of new-onset diabetes after kidney transplant (NODAT). Up to one-third of&#xD;
      previously non-diabetic patients develop NODAT after a kidney transplant. Corticosteroids and&#xD;
      calcineurin inhibitors are two commonly utilized anti-rejection medications that contribute&#xD;
      to diabetes development through multiple mechanisms; including decreased insulin production&#xD;
      by the pancreas. Sitagliptin is an oral medication that results in increased insulin&#xD;
      secretion. We hypothesize that administration of sitagliptin to transplant recipients&#xD;
      identified to be at risk for diabetes development will reduce the incidence and severity of&#xD;
      NODAT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-center, randomized, double-blind trial to evaluate the efficacy of&#xD;
      sitagliptin to prevent the development of new-onset diabetes after transplant (NODAT) in&#xD;
      previously non-diabetic patients with post-operative hyperglycemia following living-donor or&#xD;
      deceased-donor kidney transplant. In this trial, previously non-diabetic adult patients with&#xD;
      hyperglycemia (random blood sugar &gt;200mg/dL) in the first 72 hours following kidney&#xD;
      transplant will be screened to determine eligibility based on inclusion/exclusion criteria.&#xD;
      Patients that meet study entry criteria will be stratified based on HbA1c (&lt;5.7 or 5.7-6.4%)&#xD;
      and randomized in a 1:1 ratio to one of two treatment groups: sitagliptin versus placebo.&#xD;
      Fifty patients (25 per group) will be enrolled. Dosing period will be 3 months at which time&#xD;
      study drug will be discontinued and patients will be followed for an additional 3 month&#xD;
      period.&#xD;
&#xD;
      Study visits will occur at 0, 1, 3 and 6 months. A HbA1c and 2-hour oral glucose tolerance&#xD;
      test (OGTT) will be obtained at the 3 and 6 month study visit.&#xD;
&#xD;
      Screening period (Visit 1)&#xD;
&#xD;
      All patients presenting for living-donor or deceased donor kidney transplant will have a&#xD;
      medical history, medication history, vital signs, height, weight, body mass index, physical&#xD;
      exam, random blood sugar (BS), HbA1c and EKG done as part of routine pre-transplant protocol&#xD;
      at Barnes Jewish Hospital. Patients with hyperglycemia, defined as a random blood sugar ≥ 200&#xD;
      mg/dL, in the first 72 hours after kidney transplant will be screened to determine&#xD;
      eligibility for the study based on inclusion and exclusion criteria.&#xD;
&#xD;
      Randomization (Visit 2)&#xD;
&#xD;
      Patients meeting study entry criteria and consenting to study participation will be&#xD;
      stratified based on HbA1c (&lt;5.7 or 5.7-6.4%) and block randomized in blocks of eight in a 1:1&#xD;
      ratio to sitagliptin versus placebo. Sitagliptin dose will be 100mg/day, adjusted per&#xD;
      creatinine clearance and tolerability. Patients will be instructed by a licensed diabetic&#xD;
      educator on proper measurement and recording of fasting and post-prandial blood sugars.&#xD;
      Subjects will be provided a log, standard glucometer and testing strips to maintain a blood&#xD;
      sugar log post-discharge. Visit 2 will occur within 24 hours after Visit 1.&#xD;
&#xD;
      Drug dosing period (Visits 3-4)&#xD;
&#xD;
      Sitagliptin or placebo will be continued until 3 months post-transplant, at which time study&#xD;
      medication will be discontinued and collected from the subject. At the 1 and 3 month visits,&#xD;
      vital signs, height, weight, and BMI will be obtained. A physical exam will be performed.&#xD;
      Blood sugar logs provided by the patient will be reviewed and adverse effects recorded. At&#xD;
      the 3 month visit (Visit 4), a HbA1c, 2-hour OGTT, fasting C-peptide and insulin level will&#xD;
      be obtained.&#xD;
&#xD;
      Follow-up (Visit 5)&#xD;
&#xD;
      At the 6 month final visit, 3 months following discontinuation of study medication, vital&#xD;
      signs, height, weight, BMI, HbA1c, 2-hour OGTT, fasting C-peptide and insulin level will be&#xD;
      obtained. A physical exam will be performed. Blood sugar logs provided by the patient will be&#xD;
      reviewed and adverse effects recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-hour Oral Glucose Tolerance Test-derived Blood Sugar</measure>
    <time_frame>3 months</time_frame>
    <description>Change in 2-hour OGTT-derived blood sugar will be measured from three months to six months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normal 2-hour Oral Glucose Tolerance Test-derived Blood Sugar</measure>
    <time_frame>3 months</time_frame>
    <description>Number of subjects who have normal 2-hour oral glucose tolerance test-derived blood sugar will be measured at 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Posttransplant Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitaglipitin tablets will be administered orally for 3 months from randomization&#xD;
Initial dose will be 100mg/daily, adjusted per renal function:&#xD;
Creatinine clearance &gt; or = 50mL/min: 100mg/day Creatinine clearance &gt; or = 30 and &lt;50mL/min: 50mg/day Creatinine clearance &lt;30 mL/min or on dialysis: 25mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (≥18 yo) recipient of living-donor or deceased donor kidney transplant&#xD;
&#xD;
          2. Blood sugar ≥ 200 mg/dL in first 72 hours after transplant&#xD;
&#xD;
          3. No history of diabetes or prior treatment with insulin or oral hypoglycemic agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A1c of ≥6.5% measured immediately pre-transplant&#xD;
&#xD;
          2. Recipient of simultaneous kidney-pancreas, kidney-liver, kidney-heart, or kidney-lung&#xD;
             transplant&#xD;
&#xD;
          3. Prior non-renal solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rowena Delos Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yates CJ, Fourlanos S, Hjelmesaeth J, Colman PG, Cohney SJ. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant. 2012 Apr;12(4):820-8. doi: 10.1111/j.1600-6143.2011.03855.x. Epub 2011 Nov 28. Review.</citation>
    <PMID>22123607</PMID>
  </reference>
  <reference>
    <citation>Caillard S, Eprinchard L, Perrin P, Braun L, Heibel F, Moreau F, Kessler L, Moulin B. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation. 2011 Apr 15;91(7):757-64. doi: 10.1097/TP.0b013e31820f0877.</citation>
    <PMID>21336240</PMID>
  </reference>
  <reference>
    <citation>Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, Mulligan DC, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol. 2010 Sep;5(9):1669-75. doi: 10.2215/CJN.09481209. Epub 2010 Jun 17.</citation>
    <PMID>20558559</PMID>
  </reference>
  <reference>
    <citation>Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.</citation>
    <PMID>16912128</PMID>
  </reference>
  <reference>
    <citation>Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011 Nov 27;92(10):e56-7. doi: 10.1097/TP.0b013e3182347ea4.</citation>
    <PMID>22067216</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <results_first_submitted>June 4, 2021</results_first_submitted>
  <results_first_submitted_qc>June 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>transplant</keyword>
  <keyword>kidney</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT01928199/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>Sitaglipitin tablets will be administered orally for 3 months from randomization&#xD;
Initial dose will be 100mg/daily, adjusted per renal function:&#xD;
Creatinine clearance &gt; or = 50mL/min: 100mg/day Creatinine clearance &gt; or = 30 and &lt;50mL/min: 50mg/day Creatinine clearance &lt;30 mL/min or on dialysis: 25mg/day&#xD;
Sitagliptin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We measured baseline hemoglobin A1c</population>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>Sitaglipitin tablets will be administered orally for 3 months from randomization&#xD;
Initial dose will be 100mg/daily, adjusted per renal function:&#xD;
Creatinine clearance &gt; or = 50mL/min: 100mg/day Creatinine clearance &gt; or = 30 and &lt;50mL/min: 50mg/day Creatinine clearance &lt;30 mL/min or on dialysis: 25mg/day&#xD;
Sitagliptin</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.71" spread="12.63"/>
                    <measurement group_id="B2" value="51.81" spread="16.54"/>
                    <measurement group_id="B3" value="51.34" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.27" spread="0.46"/>
                    <measurement group_id="B2" value="5.13" spread="0.41"/>
                    <measurement group_id="B3" value="5.20" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>2-hour Oral Glucose Tolerance Test-derived Blood Sugar</title>
        <description>Change in 2-hour OGTT-derived blood sugar will be measured from three months to six months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitaglipitin tablets will be administered orally for 3 months from randomization&#xD;
Initial dose will be 100mg/daily, adjusted per renal function:&#xD;
Creatinine clearance &gt; or = 50mL/min: 100mg/day Creatinine clearance &gt; or = 30 and &lt;50mL/min: 50mg/day Creatinine clearance &lt;30 mL/min or on dialysis: 25mg/day&#xD;
Sitagliptin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>2-hour Oral Glucose Tolerance Test-derived Blood Sugar</title>
          <description>Change in 2-hour OGTT-derived blood sugar will be measured from three months to six months</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.00" spread="62.44"/>
                    <measurement group_id="O2" value="165.22" spread="72.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normal 2-hour Oral Glucose Tolerance Test-derived Blood Sugar</title>
        <description>Number of subjects who have normal 2-hour oral glucose tolerance test-derived blood sugar will be measured at 3 months</description>
        <time_frame>3 months</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Adverse events related to admissions described were part of post transplant events, determined not due to medication side effects</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>Sitaglipitin tablets will be administered orally for 3 months from randomization&#xD;
Initial dose will be 100mg/daily, adjusted per renal function:&#xD;
Creatinine clearance &gt; or = 50mL/min: 100mg/day Creatinine clearance &gt; or = 30 and &lt;50mL/min: 50mg/day Creatinine clearance &lt;30 mL/min or on dialysis: 25mg/day&#xD;
Sitagliptin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Volume overload</sub_title>
                <description>Admission during study period for volume overload requiring diuresis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <description>Patient was evaluated for shortness of breath during study period; no other additional events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right arm weakness</sub_title>
                <description>Patient was evaluated for right arm weakness; no other significant findings additionally</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine leak</sub_title>
                <description>Patient experienced urine leak during study period, requiring admission and repair</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bilateral native nephrectomy</sub_title>
                <description>Patient underwent elective bilateral native nephrectomy surgery during study period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hernia repair</sub_title>
                <description>Patient underwent elective hernia repair during study period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rowena Delos Santos</name_or_title>
      <organization>Washington University in St. Louis</organization>
      <phone>314-362-8351</phone>
      <email>delossantos@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

